Docetaxel Polymeric Micelles not checked
Jiangsu Simcere Pharmaceutical Co., Ltd. · SIM0388
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Malignant Ascites
- Main trialPhase 1
- “Malignant Ascites is a common complication of malignant tumor. The objective of this study is to evaluate the safety, efficacy, and pharmacokinetic characteristics of intraperitoneal perfusion with Docetaxel Polymeric Micelles (SIM0388) for injection in patients with malignant ascites”In the company’s words, NCT07007988 on ClinicalTrials.gov
- Other names
- SIM0388
Other drugs for Malignant Ascites
- EndostarJiangsu Simcere Pharmaceutical Co., Ltd. · Phase 3
- JMKX000197Jemincare · Phase 2
- M701Wuhan YZY Biopharma Co., Ltd. · Phase 1/2
- WSK-IM02WestVac Biopharma Co., Ltd. · Phase 1
- MT027Suzhou Maximum Bio-tech Co., Ltd. · Phase 1
Coming up1
- Jun 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Jun 2027 | A Phase I Study of SIM0388 in Participants With Malignant Ascites. | |
| Phase 2Unknown | Dec 2022 | A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026